Tyrian, Becton Dickinson End POC TB Dx Partnership | GenomeWeb

NEW YORK (GenomeWeb News) — Australian firm Tyrian Diagnostics said today that it has discontinued its collaboration with Becton Dickinson to develop a point-of-care diagnostic for active tuberculosis, as neither firm was able to consistently detect Tyrian's lead protein biomarker in clinical samples at high enough sensitivity and specificity levels.

Tyrian and BD entered into a collaboration and licensing deal in July 2007 to develop and commercialize TB diagnostic tests based upon biomarkers discovered by Tyrian.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.